{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:11:37Z","timestamp":1781629897970,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170453"],"award-info":[{"award-number":["No. 82170453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coronary artery disease (CAD) is a chronic inflammatory condition, with cytokines playing a crucial role. However, their involvement in premature CAD (pCAD) remains unclear. This study investigates the relationship between cytokines and pCAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 986 patients (males\u2009\u2264\u200955 years, females\u2009\u2264\u200965 years) were classified into pCAD and non-CAD groups based on coronary angiography. Serum levels of 12 cytokines, including Interleukin\u20131\u03b2 (IL\u20131\u03b2), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, tumor necrosis factor\u2013\u03b1 (TNF\u2013\u03b1), interferon\u2013\u03b1 (IFN\u2013\u03b1), and IFN-\u03b3, were measured. Spearman correlation and binary logistic regression were used to evaluate the relationship between cytokines and pCAD. The predictive performance of the multivariable logistic regression model was evaluated using ROC curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum levels of IL-6 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and IL-17 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.048) were significantly higher in the pCAD group. In males, both IL-6 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039) and IL-17 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039) levels were higher compared to non-CAD, while in females, only IL-6 was significantly different (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008). Moreover, IL-6 showed moderate positive correlations with hsTnI (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.490,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and hsCRP (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.542,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). IL-17 (OR\u2009=\u20091.042, 95% CI: 1.005\u20131.080,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.026), hsTnI (OR\u2009=\u20091.038, 95% CI: 1.008\u20131.069,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.014), diabetes (OR\u2009=\u20091.903, 95% CI: 1.160\u20133.121,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.011), and aspirin use (OR\u2009=\u20091.766, 95% CI: 1.131\u20132.757,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.010) were independent risk factors for pCAD. ROC analysis showed an AUC of 0.792 for the full model and 0.747 for significant predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL-6 and IL-17 were significantly higher in the pCAD group. IL-6 was positively correlated with hsTnI and hsCRP. IL-17, hsTnI, diabetes, and aspirin use were independent risk factors, highlighting inflammation\u2019s significance in pCAD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-05227-0","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:52:42Z","timestamp":1768881162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-6 and lL-17 as potential biomarkers for premature coronary artery disease: a cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"given":"Kexin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"10440","key":"5227_CR1","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2100\u201332.","journal-title":"Lancet"},{"key":"5227_CR2","doi-asserted-by":"publisher","unstructured":"Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW et al. Heart Disease and Stroke Statistics\u20142021 Update: A Report From the American Heart Association. Circulation [Internet]. 2021 Feb 23 [cited 2024 Oct 8];143(8). Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/CIR.0000000000000950","DOI":"10.1161\/CIR.0000000000000950"},{"issue":"19","key":"5227_CR3","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"EPO Detection","year":"2001","unstructured":"Detection EPO. Evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA: J Am Med Assoc. 2001;285(19):2486\u201397.","journal-title":"JAMA: J Am Med Assoc"},{"key":"5227_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1236837","volume":"2018","author":"TT Tian","year":"2018","unstructured":"Tian TT, Li H, Chen SJ, Wang Q, Tian QW, Zhang BB, et al. Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: a case-control study. Dis Markers. 2018;2018:1\u20138.","journal-title":"Dis Markers"},{"issue":"8","key":"5227_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/jim-2021-002134","volume":"70","author":"A Rafiei","year":"2022","unstructured":"Rafiei A, Ahmadi R, Kazemian S, Rahimzadeh-Fallah T, Mohammad-Rezaei M, Azadegan-Dehkordi F, et al. Serum levels of IL-37 and correlation with inflammatory cytokines and clinical outcomes in patients with coronary artery disease. J Investig Med. 2022;70(8):1720\u20137.","journal-title":"J Investig Med"},{"issue":"4","key":"5227_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","volume":"162","author":"PM Ridker","year":"2011","unstructured":"Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J. 2011;162(4):597\u2013605.","journal-title":"Am Heart J"},{"issue":"11","key":"5227_CR7","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.2337\/dc22-0866","volume":"45","author":"A Koshino","year":"2022","unstructured":"Koshino A, Schechter M, Sen T, Vart P, Neuen BL, Neal B, et al. Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS. Diabetes Care. 2022;45(11):2644\u201352.","journal-title":"Diabetes Care"},{"issue":"8","key":"5227_CR8","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3390\/life13081669","volume":"13","author":"Y Dimitroglou","year":"2023","unstructured":"Dimitroglou Y, Aggeli C, Theofilis P, Tsioufis P, Oikonomou E, Chasikidis C, et al. Novel anti-inflammatory therapies in coronary artery disease and acute coronary syndromes. Life. 2023;13(8):1669.","journal-title":"Life"},{"issue":"6","key":"5227_CR9","first-page":"704","volume":"11","author":"DC Oliveira","year":"2021","unstructured":"Oliveira DC, Oliveira CGC, Mendes EB, Silveira MM, Cabral JV, Ferreira E. Circulating interleukin-17a in patients with acute and chronic coronary syndromes. Am J Cardiovasc Dis. 2021;11(6):704\u20139.","journal-title":"Am J Cardiovasc Dis"},{"key":"5227_CR10","doi-asserted-by":"publisher","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). [cited 2025 Sep 8]; Available from: https:\/\/doi.org\/10.1093\/eurheartj\/ehz425","DOI":"10.1093\/eurheartj\/ehz425"},{"issue":"24","key":"5227_CR11","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology Foundation\/American heart association task force on practice guidelines, and the American college of Physicians, American association for thoracic Surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and Interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2012;60(24):e44\u2013164.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"5227_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/JCN.0000000000000150","volume":"30","author":"DMT Tran","year":"2015","unstructured":"Tran DMT, Zimmerman LM. Cardiovascular risk factors in young adults: a literature review. J Cardiovasc Nurs. 2015;30(4):298\u2013310.","journal-title":"J Cardiovasc Nurs"},{"issue":"7","key":"5227_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13124","volume":"49","author":"H Poorzand","year":"2019","unstructured":"Poorzand H, Tsarouhas K, Hozhabrossadati SA, Khorrampazhouh N, Bondarsahebi Y, Bacopoulou F, et al. Risk factors of premature coronary artery disease in Iran: a systematic review and meta-analysis. Eur J Clin Invest. 2019;49(7):e13124.","journal-title":"Eur J Clin Invest"},{"key":"5227_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6762089","volume":"2019","author":"Y Qu","year":"2019","unstructured":"Qu Y, Yang J, Zhang F, Li C, Dai Y, Yang H, et al. Gender-related differences in clinical characteristics and outcomes of premature coronary artery disease: insight from the FOCUS registry. J Interv Cardiol. 2019;2019:1\u20138.","journal-title":"J Interv Cardiol"},{"issue":"1","key":"5227_CR15","volume":"4","author":"X Liu","year":"2025","unstructured":"Liu X, Wu Y, Li F, Qi X, Niu L, Wu Y, et al. Global burden of early-onset ischemic heart disease, 1990 to 2019. JACC: Advances. 2025;4(1):101466.","journal-title":"JACC: Advances"},{"issue":"15","key":"5227_CR16","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.jacc.2019.08.1002","volume":"74","author":"JP Collet","year":"2019","unstructured":"Collet JP, Zeitouni M, Procopi N, Hulot JS, Silvain J, Kerneis M, et al. Long-Term evolution of premature coronary artery disease. J Am Coll Cardiol. 2019;74(15):1868\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"5227_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7326\/0003-4819-128-2-199801150-00009","volume":"128","author":"DA Papanicolaou","year":"1998","unstructured":"Papanicolaou DA. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128(2):127.","journal-title":"Ann Intern Med"},{"issue":"5","key":"5227_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MCA.0b013e32820588ae","volume":"18","author":"C Sekuri","year":"2007","unstructured":"Sekuri C, Cam FS, Sagcan A, Ercan E, Tengiz I, Alioglu E, et al. No association of interleukin-6 gene polymorphism (-174 G\/C) with premature coronary artery disease in a Turkish cohort. Coron Artery Dis. 2007;18(5):333\u20137.","journal-title":"Coron Artery Dis"},{"issue":"3","key":"5227_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1365-2249.1998.00612.x","volume":"112","author":"M Mihara","year":"2001","unstructured":"Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB\/W F1 mice. Clin Exp Immunol. 2001;112(3):397\u2013402.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"5227_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","volume":"180","author":"S Kitaba","year":"2012","unstructured":"Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012;180(1):165\u201376.","journal-title":"Am J Pathol"},{"issue":"8","key":"5227_CR21","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/art.24689","volume":"60","author":"N Okiyama","year":"2009","unstructured":"Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009;60(8):2505\u201312.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5227_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/1043-4666(94)90013-2","volume":"6","author":"Y Seino","year":"1994","unstructured":"Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994;6(1):87\u201391.","journal-title":"Cytokine"},{"key":"5227_CR23","doi-asserted-by":"publisher","unstructured":"Inflammatory Biomarkers Interleukin-6. and C\u2010Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial | Journal of the American Heart Association [Internet]. [cited 2025 Sep 7]. Available from: https:\/\/www.ahajournals.org\/doi\/abs\/https:\/\/doi.org\/10.1161\/jaha.116.005077","DOI":"10.1161\/jaha.116.005077"},{"issue":"1","key":"5227_CR24","volume":"10","author":"M Haji Aghajani","year":"2022","unstructured":"Haji Aghajani M, Toloui A, Ahmadzadeh K, Madani Neishaboori A, Yousefifard M. Premature coronary artery disease and plasma levels of interleukins; a systematic scoping review and meta-analysis. Arch Acad Emerg Med. 2022;10(1):e51.","journal-title":"Arch Acad Emerg Med"},{"key":"5227_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2024.104886","volume":"136","author":"R Posadas-S\u00e1nchez","year":"2024","unstructured":"Posadas-S\u00e1nchez R, L\u00f3pez-Uribe \u00c1R, Fragoso JM, Vargas-Alarc\u00f3n G. Interleukin 6 polymorphisms are associated with cardiovascular risk factors in premature coronary artery disease patients and healthy controls of the GEA Mexican study. Exp Mol Pathol. 2024;136:104886.","journal-title":"Exp Mol Pathol"},{"issue":"12","key":"5227_CR26","doi-asserted-by":"publisher","first-page":"9768","DOI":"10.3390\/cimb45120610","volume":"45","author":"N P\u00e9rez-Hern\u00e1ndez","year":"2023","unstructured":"P\u00e9rez-Hern\u00e1ndez N, Posadas-S\u00e1nchez R, Vargas-Alarc\u00f3n G, P\u00e9rez-M\u00e9ndez \u00d3, Luna-Luna M, Rodr\u00edguez-P\u00e9rez JM. DNA methylation of the IL-17A gene promoter is associated with subclinical atherosclerosis and coronary artery disease: the genetics of atherosclerotic disease Mexican study. Curr Issues Mol Biol. 2023;45(12):9768\u201377.","journal-title":"Curr Issues Mol Biol"},{"key":"5227_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3389\/fimmu.2019.01293","volume":"10","author":"S Swaidani","year":"2019","unstructured":"Swaidani S, Liu C, Zhao J, Bulek K, Li X. TRAF regulation of IL-17 cytokine signaling. Front Immunol. 2019;10:1293.","journal-title":"Front Immunol"},{"issue":"8","key":"5227_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/eurheartj\/ehs399","volume":"34","author":"G Liuzzo","year":"2013","unstructured":"Liuzzo G, Trotta F, Pedicino D. Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J. 2013;34(8):556\u20139.","journal-title":"Eur Heart J"},{"issue":"9","key":"5227_CR29","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.4049\/jimmunol.1400181","volume":"193","author":"C Erbel","year":"2014","unstructured":"Erbel C, Akhavanpoor M, Okuyucu D, Wangler S, Dietz A, Zhao L, et al. IL-17A influences essential functions of the monocyte\/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol. 2014;193(9):4344\u201355.","journal-title":"J Immunol"},{"key":"5227_CR30","doi-asserted-by":"crossref","unstructured":"Mahmoudi-Nejad S, Esm-Khani L, Mahmudi S, Khadem-Vatani K, Abdi Rad I, Bagheri M. Evaluation of interleukin-17 receptor (IL-17RA) gene expression in PBMCs of patients with premature coronary artery disease. Bratisl Med J [Internet]. 2022 Jul 23 [cited 2024 Nov 30];123(10). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35913009\/","DOI":"10.4149\/BLL_2022_118"},{"issue":"1","key":"5227_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00395-010-0135-y","volume":"106","author":"C Erbel","year":"2011","unstructured":"Erbel C, Dengler TJ, Wangler S, Lasitschka F, Bea F, Wambsganss N, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol. 2011;106(1):125\u201334.","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"5227_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13578-020-00400-8","volume":"10","author":"SF Chang","year":"2020","unstructured":"Chang SF, Liu SF, Chen CN, Kuo HC. Serum IP-10 and IL-17 from Kawasaki disease patients induce calcification-related genes and proteins in human coronary artery smooth muscle cells in vitro. Cell Biosci. 2020;10(1):36.","journal-title":"Cell Biosci"},{"key":"5227_CR33","doi-asserted-by":"crossref","unstructured":"Khadem-Vatani K, Bagheri M, Rad IA, Mahmoudi-Nejad S, Hassan-Nejad M. Interleukin-17 is Not Associated with Risk of Premature Coronary Artery Disease in Iranian Turks. Maedica - J Clin Med [Internet]. 2020 Jun 15 [cited 2024 Nov 30];15(2). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32952682\/","DOI":"10.26574\/maedica.2020.15.2.181"},{"issue":"8","key":"5227_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.4244\/EIJV8I8A142","volume":"8","author":"J Ruiz-Garc\u00eda","year":"2012","unstructured":"Ruiz-Garc\u00eda J, Lerman A, Weisz G, Maehara A, Mintz GS, Fahy M, et al. Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. EuroIntervention. 2012;8(8):929\u201338.","journal-title":"EuroIntervention"},{"key":"5227_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.320259","author":"K Reue","year":"2022","unstructured":"Reue K, Wiese CB. Illuminating the mechanisms underlying sex differences in cardiovascular disease. Circ Res. 2022. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.320259.","journal-title":"Circ Res"},{"issue":"3","key":"5227_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.33678\/cor.2022.057","volume":"65","author":"L Askin","year":"2023","unstructured":"Askin L, Tanriverdi O. Humanin and cardiovascular diseases. Cor Vasa. 2023;65(3):533\u20137.","journal-title":"Cor Vasa"},{"issue":"11","key":"5227_CR37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","volume":"18","author":"K Matsushita","year":"2022","unstructured":"Matsushita K, Ballew SH, Wang AYM, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696\u2013707.","journal-title":"Nat Rev Nephrol"},{"key":"5227_CR38","doi-asserted-by":"crossref","unstructured":"Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2022 Mar [cited 2024 Nov 30];145(9). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35000404\/","DOI":"10.1161\/CIR.0000000000001040"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05227-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:49:18Z","timestamp":1781628558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05227-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5227"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05227-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Beijing Anzhen Hospital (Approval No.2020025X). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}